Please find enclosed Outcome of the Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech Ltd reported its FY25 audited results on May 19, 2025. Standalone revenue from operations grew modestly to Rs 4,661.25 Lacs (vs Rs 4,488.05 Lacs in FY24). Net profit after tax jumped sharply to Rs 757.07 Lacs from Rs 252.22 Lacs in FY24, a roughly three-fold increase, driven largely by a Rs 461.50 Lacs profit on sale of property, plant and equipment included in other income. Consolidated PAT rose to Rs 728.26 Lacs from Rs 252.62 Lacs. Q4 standalone PAT was Rs 118.58 Lacs (vs Rs 69.77 Lacs in Q4 FY24). EPS for FY25 stood at Rs 4.95 (vs Rs 1.69). Statutory auditor P. Murali & Co. issued an unmodified opinion on both standalone and consolidated results, with an emphasis of matter flagging that the company has been irregular in depositing undisputed statutory dues (PF, ESI, Professional Tax, TDS, and Income Tax totaling about Rs 337.63 Lacs) as of March 31, 2025.
The sharp jump in profits is positive on the surface, but a large chunk comes from a one-time asset sale, so core operating performance is less impressive than the headline PAT suggests. The auditor's emphasis on unpaid statutory dues totaling over Rs 3.3 Cr is a red flag on compliance and governance that shareholders should watch, though it did not affect the clean audit opinion.